To extend the Malibu-Glo assay to other antigens for treatment of hematologic malignancies and solid tumors, we generated Malibu-Glo reagents based on scFvs targeting CD20, CD30, CD33, BCMA, CD138 and CS1. The gene discussed is TNFRSF17; the disease is hematologic disorder.